🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Shilpa Medicare Limited SHILPAMED NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.vbshilpa.com
Company Profile ↓
₹632.50
+45.54% 1Y
Mkt Cap₹12,370.55 Cr
P/E50.84
P/B4.76
Div. Yield0.08%
52W High₹632.50
52W Low₹267.00
Book Value₹132.49
EPS (TTM)₹12.44

Company Overview

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 282.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 13.8% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 15.8%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.25.

Recent Developments

  • Mar 2026 Revenue of ₹1,538.87 Cr (+19.6% YoY); net profit ₹243.33 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.6%, earnings +210.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.8%, profit CAGR 282.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.83%
1 Year:19.62%

Compounded Profit Growth

5 Years:282.65%
1 Year:210.77%

Stock Price Performance

1 Year:+45.54%
6 Months:+109.68%
3 Months:+53.52%
1 Month:+18.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹267.00 ₹632.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)67.76 · Neutral
Price Performance
1M+18.72%
3M+53.52%
6M+109.68%
1Y+45.54%
Valuation vs Sector

P/E of 50.84 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 13.8% over 5 years.
  • Profit CAGR of 282.6% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 50.8.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
50.84
Industry PE
39.97
Forward P/E
34.19
PEG Ratio
-
Book Value
₹132.49
Price to Book
4.76
P/S
8.01
EV/EBITDA
29.77
Dividend Yield
0.08%

Growth (CAGR)

Revenue 5Y
13.83%
Profit 5Y
282.65%
Revenue (YoY)
19.62%
Earnings (YoY)
210.77%

Profitability & Returns

ROCE
14.52%
ROE
9.39%
ROA
6.57%
Profit Margin
15.81%
Op Margin
24.43%
Gross Margin
70.08%
EPS (Latest Qtr)
₹5.51
EPS (TTM)
₹12.44

Balance Sheet & Liquidity

Debt/Equity
0.25
Quick Ratio
0.88
Current Ratio
1.31
Debt
₹659.86 Cr
Total Assets
₹3,705.61 Cr
Current Assets
₹1,109.77 Cr
Working Capital
₹261.71 Cr

Ownership

Promoter Holding
55.38%
Chg in Prom Hold
-5.14%
FII / Inst Holding
10.65%
Chg in FII Hold
0.07%

Financial Snapshot

Enterprise Value
₹12,370.55 Cr
Total Revenue (TTM)
₹1,538.87 Cr
EBITDA
₹534.75 Cr
Free Cash Flow
₹-28.45 Cr
Operating Cash Flow
₹342.18 Cr
Shares Outstanding
₹19.56 Cr
Gross Margin
70.08%
Payout Ratio
4.02%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SHILPAMED Shilpa Medicare Limited NSEPHARMA 632.50 50.84 ₹12,370.55 Cr 0.08% 14.52% 9.39% 13.83% 282.65%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 264.00 Cr260.00 Cr313.00 Cr287.00 Cr292.00 Cr293.00 Cr344.00 Cr319.00 Cr330.82 Cr321.46 Cr369.97 Cr409.73 Cr436.99 Cr
Cost of Revenue --------104.49 Cr79.61 Cr105.50 Cr133.32 Cr141.99 Cr
Gross Profit --------226.33 Cr241.85 Cr264.47 Cr276.40 Cr295.00 Cr
Operating Expenses 227.00 Cr214.00 Cr255.00 Cr222.00 Cr222.00 Cr222.00 Cr258.00 Cr239.00 Cr161.61 Cr179.14 Cr186.01 Cr192.47 Cr188.95 Cr
Operating Income 11.00 Cr19.00 Cr30.00 Cr38.00 Cr43.00 Cr43.00 Cr58.00 Cr52.00 Cr64.72 Cr62.72 Cr78.46 Cr83.94 Cr106.05 Cr
EBITDA 37.00 Cr46.00 Cr58.00 Cr65.00 Cr70.00 Cr70.00 Cr86.00 Cr81.00 Cr58.55 Cr97.28 Cr109.92 Cr101.90 Cr164.73 Cr
Interest Expense 18.00 Cr18.00 Cr23.00 Cr26.00 Cr24.00 Cr24.00 Cr26.00 Cr12.00 Cr28.79 Cr18.78 Cr15.67 Cr10.68 Cr30.62 Cr
Pretax Income -4.00 Cr3.00 Cr9.00 Cr14.00 Cr28.00 Cr29.00 Cr37.00 Cr42.00 Cr15.27 Cr49.58 Cr64.43 Cr60.85 Cr120.45 Cr
Tax Provision -3.60 Cr1.92 Cr7.47 Cr9.38 Cr3.36 Cr14.79 Cr18.87 Cr10.08 Cr77.00 L2.69 Cr20.36 Cr16.27 Cr12.66 Cr
Net Income -8.00 Cr1.00 Cr2.00 Cr5.00 Cr24.00 Cr14.00 Cr18.00 Cr32.00 Cr14.51 Cr46.89 Cr44.07 Cr44.58 Cr107.79 Cr
Diluted EPS -0.460.070.090.261.410.720.921.620.742.401.122.365.51

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 614.00 Cr719.00 Cr779.00 Cr789.00 Cr733.00 Cr908.00 Cr899.00 Cr-1,043.45 Cr1,150.84 Cr1,286.43 Cr1,538.87 Cr
Cost of Revenue --------416.84 Cr408.04 Cr410.39 Cr460.41 Cr
Gross Profit --------626.60 Cr742.80 Cr876.04 Cr1,078.46 Cr
Operating Expenses 485.00 Cr566.00 Cr614.00 Cr634.00 Cr585.00 Cr688.00 Cr718.00 Cr-631.20 Cr608.94 Cr632.20 Cr702.54 Cr
Operating Income 108.00 Cr124.00 Cr134.00 Cr118.00 Cr106.00 Cr175.00 Cr127.00 Cr--4.60 Cr133.86 Cr243.84 Cr375.92 Cr
EBITDA 129.00 Cr153.00 Cr165.00 Cr155.00 Cr148.00 Cr219.00 Cr181.00 Cr-113.47 Cr245.92 Cr348.31 Cr534.75 Cr
Interest Expense 4.00 Cr7.00 Cr3.00 Cr3.00 Cr4.00 Cr5.00 Cr22.00 Cr-56.25 Cr83.71 Cr112.99 Cr119.72 Cr
Pretax Income 108.00 Cr122.00 Cr146.00 Cr137.00 Cr136.00 Cr188.00 Cr195.00 Cr--38.28 Cr54.34 Cr122.33 Cr295.31 Cr
Tax Provision 35.64 Cr23.18 Cr42.34 Cr34.25 Cr25.84 Cr33.84 Cr48.75 Cr--7.31 Cr22.39 Cr44.04 Cr51.99 Cr
Net Income 73.00 Cr99.00 Cr104.00 Cr103.00 Cr110.00 Cr155.00 Cr146.00 Cr--32.53 Cr31.87 Cr78.30 Cr243.33 Cr
Diluted EPS 4.786.736.716.456.889.579.06--1.881.834.0212.44

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 905.00 Cr1,062.00 Cr1,472.00 Cr1,499.00 Cr1,610.00 Cr1,989.00 Cr2,632.00 Cr-2,903.93 Cr3,093.24 Cr3,310.71 Cr3,705.61 Cr
Current Assets --------769.55 Cr876.24 Cr985.67 Cr1,109.77 Cr
Cash & Equivalents --------21.32 Cr30.23 Cr25.97 Cr41.26 Cr
Inventory --------319.82 Cr344.93 Cr347.93 Cr366.79 Cr
Receivables --------324.35 Cr392.05 Cr440.84 Cr518.85 Cr
Total Liabilities --------1,129.57 Cr1,293.29 Cr947.01 Cr1,114.41 Cr
Current Liabilities --------784.45 Cr693.59 Cr674.23 Cr848.06 Cr
Long Term Debt --------288.82 Cr560.16 Cr231.96 Cr183.81 Cr
Total Debt 189.00 Cr221.00 Cr241.00 Cr191.00 Cr194.00 Cr390.00 Cr846.00 Cr-797.89 Cr937.39 Cr587.75 Cr659.86 Cr
Total Equity 547.00 Cr647.00 Cr987.00 Cr1,085.00 Cr1,197.00 Cr1,329.00 Cr1,479.00 Cr-1,783.28 Cr1,801.08 Cr2,363.07 Cr2,591.20 Cr
Shares Outstanding --------8.68 Cr8.68 Cr9.78 Cr19.56 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 69.00 Cr129.00 Cr37.00 Cr45.00 Cr147.00 Cr124.00 Cr47.00 Cr-179.92 Cr136.67 Cr132.27 Cr342.18 Cr
Investing Cash Flow -196.00 Cr-106.00 Cr-257.00 Cr-10.00 Cr-196.00 Cr-290.00 Cr-404.00 Cr--232.61 Cr-166.58 Cr-199.13 Cr-325.92 Cr
Financing Cash Flow 136.00 Cr-20.00 Cr313.00 Cr-61.00 Cr10.00 Cr176.00 Cr436.00 Cr-45.80 Cr46.77 Cr62.65 Cr13.62 Cr
Capital Expenditure -143.00 Cr-117.00 Cr-116.00 Cr-137.00 Cr-298.00 Cr-344.00 Cr-349.00 Cr--226.67 Cr-184.56 Cr-243.68 Cr-370.63 Cr
Free Cash Flow -74.00 Cr12.00 Cr-79.00 Cr-92.00 Cr-151.00 Cr-220.00 Cr-302.00 Cr--46.74 Cr-47.89 Cr-111.41 Cr-28.45 Cr
Net Change in Cash 9.00 Cr3.00 Cr93.00 Cr-26.00 Cr-39.00 Cr10.00 Cr79.00 Cr--6.89 Cr16.86 Cr-4.21 Cr29.88 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------60.1%64.5%68.1%70.1%
Operating Margin % 17.6%17.2%17.2%15.0%14.5%19.3%14.1%--0.4%11.6%19.0%24.4%
Net Margin % 11.9%13.8%13.4%13.1%15.0%17.1%16.2%--3.1%2.8%6.1%15.8%
ROE % 13.3%15.3%10.5%9.5%9.2%11.7%9.9%--1.8%1.8%3.3%9.4%
ROCE % ---------0.2%5.6%9.2%13.2%

Shareholding Pattern

Insiders
55.38%
Institutions
10.65%
Public Float
23.87%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SHILPAMED

Google News hu, 25 Jun 2026

SHILPAMED Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE8yVkt2T0xILTF3cldyUHNPbU4yX2hfNzlZN2tBbmxQYXRuVW9QajY2VWZGRG9mZGZtV3MxZlc5d0N4NzF3MG9fdEs0ZVd2R0N2R2NVR0ZKNGlOZGRvUUdKaFUtT1gzcnZyZWdGaUlaclpUS2FmMVZ2dlNrYkY?oc=5" target="_blank">…

Google News Wed, 20 May 2026

Here's Why We Think Shilpa Medicare (NSE:SHILPAMED) Might Deserve Your Attention Today - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxNQUw3V28yOWJNVGRMekV1WmFvOWFyRHVjZUhPWVhjdEhtaDJBaUxlNTlnNTJleEJ0ZkhfRHR4NnNXVm9OQ3dlWEJ1a1N4Y2tNTGNYMVljellGV3lGT3BjYTF6djdNb2ZuLWFnckZKR081cmRCd2lFeVNMNWtmcXUyREUxSWNCaUxycU05bD…

Google News ue, 30 Jun 2026

HOT STOCKS: SHILPAMED Hits All-Time High; WSTCSTPAPR, CGCL, ARVIND, GLAND Lead Gainers; MAHSEAMLES Slips Below 100-DMA While CANFINHOME, SCHAEFFLER Climb Above 50-SMA - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMingJBVV95cUxNMHdwM0Fac2RfRWJHMm9OMDRTOXJJaXVqZHJWWV9fcHlvd3dZZXlURGJ0OFFnUnhmVUpzQkdZay1qTEJNVDZYOXJZMXZuUWZqWTNJcWJhNHVpbDM2LUIwQmxTNWJyd052T3YwRHo5eWlpdnhyajd1X3Z3bnM0V0F5ekU4c0ZkNzlXcU96NU…

Google News Sat, 30 May 2026

Shilpa Medicare (NSE:SHILPAMED) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPRTUtQk8zdUlVcFZVZzNrVk5kY1BxYTBhS1B2UWFaS3l4dFhrRWlHRy1aQzBhcTJaX2lybUNmbjYwbk9pNHkzTzlmekxKTUcxZU0yNWlTZV9uUXNzeFEtWG56ZG5mR1M3XzUxQ3dKbkd5RWJOM2lCSF8zbnc4dUNwdUhTYUdtZTJuUFBod1…

Google News ue, 16 Sep 2025

We Take A Look At Why Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Has Earned Their Pay Packet - webull.com

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE0tSi1GbTRlUGZqbDdaeEJNYWdjOEdHbldZbFdRQ05TMXZBOV9ETXZhdFRoeS1vOFpzdDJ3aEZKajdrenBXd18xeVFfNmNOamRpZzZEa0pYTTk?oc=5" target="_blank">We Take A Look At Why Shilpa Medicare Limited's …

Google News Wed, 27 May 2026

Bearish: Analysts Just Cut Their Shilpa Medicare Limited (NSE:SHILPAMED) Revenue and EPS estimates - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPVzZmYlRkbVo4eEdrTE0zdWhBSHJyR1ZQeFBEMXlHY0hQQldiMmdJLUxYWGFucEk4N2ZHQVBNYWdxaTk2WGd0VXVlUkJINHBJdUVRVXV1YVoxZ2xZVVlzY2Yxb0ZidDVlam9aeWN5STZ2Y3MyUDZCR095a0JMSmVucElZaXY4djVBUkpNc1…

SHILPAMED — Frequently Asked Questions

What is the current share price of Shilpa Medicare Limited (SHILPAMED)?

As of 2026-07-15 09:52 IST, Shilpa Medicare Limited (SHILPAMED) trades at ₹632.50 on NSE. Its 52-week range is ₹267.00 to ₹632.50.

What is the market capitalisation of SHILPAMED?

Shilpa Medicare Limited (SHILPAMED) has a market capitalisation of ₹12,370.55 Cr on NSE.

What is the P/E ratio of SHILPAMED?

SHILPAMED trades at a trailing price-to-earnings (P/E) ratio of 50.84. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.76.

Does SHILPAMED pay a dividend?

Shilpa Medicare Limited (SHILPAMED) currently offers a dividend yield of 0.08%.

What is the return on equity (ROE) of SHILPAMED?

SHILPAMED has a return on equity (ROE) of 9.39%. Its return on capital employed (ROCE) is 14.52%.

Is SHILPAMED a good stock to buy?

This page provides a data-driven analysis of Shilpa Medicare Limited (SHILPAMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space